Writing for Law360, Partner Tim Cook published an analysis overviewing the safe harbor provision that is the Hatch-Waxman Act, how it may apply in the emerging field of cell and gene therapies, and how companies can continue to work in this space while these questions are resolved.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
